Perioperative Durvalumab in Bladder Cancer: The authors reply

Thomas Powles; Matthew D. Galsky; Michiel S. van der Heijden

doi:10.1056/NEJMc2415733

Perioperative Durvalumab in Bladder Cancer: The authors reply

Thomas Powles
, Matthew D. Galsky
, Michiel S. van der Heijden

Queen Mary University of London
Icahn School of Medicine at Mount Sinai
Netherlands Cancer Institute

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	619
Number of pages	1
Journal	The New England journal of medicine
Volume	392
Issue number	6
DOIs	https://doi.org/10.1056/NEJMc2415733
Publication status	Published - 6 Feb 2025
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1056/NEJMc2415733

Cite this

@article{adcbec88b26b40bdaae8e051cdab2580,

title = "Perioperative Durvalumab in Bladder Cancer: The authors reply",

author = "Thomas Powles and Galsky, \{Matthew D.\} and \{van der Heijden\}, \{Michiel S.\}",

year = "2025",

month = feb,

day = "6",

doi = "10.1056/NEJMc2415733",

language = "English",

volume = "392",

pages = "619",

journal = "The New England journal of medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "6",

}

TY - JOUR

T1 - Perioperative Durvalumab in Bladder Cancer

T2 - The authors reply

AU - Powles, Thomas

AU - Galsky, Matthew D.

AU - van der Heijden, Michiel S.

PY - 2025/2/6

Y1 - 2025/2/6

UR - https://www.scopus.com/pages/publications/85218290743

U2 - 10.1056/NEJMc2415733

DO - 10.1056/NEJMc2415733

M3 - Comment/Letter to the editor

C2 - 39908438

SN - 0028-4793

VL - 392

SP - 619

JO - The New England journal of medicine

JF - The New England journal of medicine

IS - 6

ER -

Perioperative Durvalumab in Bladder Cancer: The authors reply

UN SDGs

Access to Document

Other files and links

Cite this